✦ LIBER ✦

Modeling the efficacy of trastuzumab-DM1, an antibody drug conjugate, in mice

✍ Scribed by Nelson L. Jumbe; Yan Xin; Douglas D. Leipold; Lisa Crocker; Debra Dugger; Elaine Mai; Mark X. Sliwkowski; Paul J. Fielder; Jay Tibbitts

Book ID: 106423554
Publisher: Springer
Year: 2010
Tongue: English
Weight: 729 KB
Volume: 37
Category: Article
ISSN: 1573-8744
DOI: 10.1007/s10928-010-9156-2

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Physicochemical Stability of the Antibod

Physicochemical Stability of the Antibody−Drug Conjugate Trastuzumab-DM1: Changes due to Modification and Conjugation Processes

✍ Wakankar, Aditya A.; Feeney, Maria B.; Rivera, Javier; Chen, Yan; Kim, Michael; 📂 Article 📅 2010 🏛 American Chemical Society 🌐 English ⚖ 237 KB

Clinical pharmacology of trastuzumab emt

Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody–drug conjugate in development for the treatment of HER2-positive cancer

✍ Sandhya Girish; Manish Gupta; Bei Wang; Dan Lu; Ian E. Krop; Charles L. Vogel; H 📂 Article 📅 2012 🏛 Springer 🌐 English ⚖ 520 KB

237 Mechanistic pharmacokinetic/pharmaco

237 Mechanistic pharmacokinetic/pharmacodynamic (PK/PD) modeling of xenograft tumor response of Trastuzumab-DM1-antibody drug conjugates

✍ R. Wada; H.K. Erickson; G. Lewis Phillips; C.A. Provenzano; D.D. Leipold; J. Pin 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 42 KB

Ado-trastuzumab emtansine (T-DM1): a nov

Ado-trastuzumab emtansine (T-DM1): a novel antibody-drug conjugate for the treatment of HER2-positive metastatic breast cancer

✍ Baron, J. M.; Boster, B. L.; Barnett, C. M. 📂 Article 📅 2014 🏛 SAGE Publications 🌐 English ⚖ 165 KB

Statistical Modeling of the Drug Load Di

Statistical Modeling of the Drug Load Distribution on Trastuzumab Emtansine (Kadcyla), a Lysine-Linked Antibody Drug Conjugate

✍ Kim, Michael T.; Chen, Yan; Marhoul, Joseph; Jacobson, Fred 📂 Article 📅 2014 🏛 American Chemical Society 🌐 English ⚖ 788 KB

Phase I Study of Trastuzumab-DM1, an HER

Phase I Study of Trastuzumab-DM1, an HER2 Antibody-Drug Conjugate, Given Every 3 Weeks to Patients With HER2-Positive Metastatic Breast Cancer

✍ Krop, I. E.; Beeram, M.; Modi, S.; Jones, S. F.; Holden, S. N.; Yu, W.; Girish, 📂 Article 📅 2010 🏛 American Society of Clinical Oncology 🌐 English ⚖ 153 KB